Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Cardiothoracic Surgery
Published in: Journal of Cardiothoracic Surgery 1/2023

Open Access 01-12-2023 | SCLC | Case Report

Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature

Authors: Zirui Zhu, You Liu, Hengliang Xu, Haoyong Ning, Yanmin Xia, Leilei Shen

Published in: Journal of Cardiothoracic Surgery | Issue 1/2023

Login to get access

Abstract

Background

Combined large cell neuroendocrine carcinoma (C-LCNEC) has a poor prognosis and there is no consensus about the treatment regimen for both LCNEC and C-LCNEC patients.

Case presentation

The patient was a 47-year-old female who received surgical resection. The postoperative histology and staging of the tumor suggested C-LCNEC with adenocarcinoma and squamous cell carcinoma and T2aN0M0 stage IB. Next-generation sequencing test showed KIF5B/RET fusion mutation without EGFR, ALK, RB1, and TP53 alterations. Adjuvant chemotherapy with 4-cycle docetaxel plus carboplatin was given and brain metastasis occurred after 10 months.

Conclusions

C-LCNEC with adenocarcinoma and squamous cell carcinoma is rare and highly aggressive cancer. Surgical resection and adjuvant chemotherapy with SCLC regimen may improve the disease-free survival and overall survival. The accumulation of similar cases will clarify the profile and management of the disease.
Literature
1.
Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: imapct of advance since 2015. J Thorc Oncol. 2021;17(3):362–87.CrossRef
2.
Fasano M, Della Corte CM, Papaccio F, et al. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10(8):1133–41.CrossRefPubMedPubMedCentral
3.
Zhang JT, Li Y, Yan LX, et al. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: a multi-center retrospective study. Lung Cancer. 2020;139:118–23.CrossRefPubMed
4.
Yang ZY, WangYN, Chen Y, et al. Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management. Eur J Cardiothorac Surg. 2022;62(2):ezac069.CrossRefPubMed
5.
Miyoshi T, Umemura S, Matsumura Y, et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23(3):757–65.CrossRefPubMed
6.
Shen Y, Hu F, Li C, et al. Clinical features and outcomes analysis of surgical resected pulmonary large-cell neuroendocrine carcinoma with adjuvant chemotherapy. Front Oncol. 2020;10:556194.CrossRefPubMedPubMedCentral
7.
Battafarano RJ, Fernandez FG, Ritter J, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130(1):166–72.CrossRefPubMed
8.
Grand B, Cazes A, Mordant P, et al. High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implications. Lung Cancer. 2013;81(3):404–9.CrossRefPubMed
9.
Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6):529–53.CrossRefPubMed
10.
Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8(7):980–4.CrossRefPubMed
11.
Le Treut J, Sault MC, Lena H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24(6):1548–52.CrossRefPubMed
12.
Kim KW, Kim HK, Kim J, et al. Outcomes of curative-intent surgery and adjuvant treatment for pulmonary large cell neuroendocrine carcinoma. World J Surg. 2017;41(7):1820–7.CrossRefPubMed
13.
Kujtan L, Muthukumar V, Kennedy KF, et al. The role of systemic therapy in the management of stage I large cell neuroendocrine carcinoma of the lung. J Thorac Oncol. 2018;13(5):707–14.CrossRefPubMed
14.
Yilmaz A, Duyar SS, Cakir E, et al. Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancer. Eur J Cardiothorac Surg. 2011;40(3):664–70.PubMed
15.
Zhuo M, Guan Y, Yang X, et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in Pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res. 2020;26(4):892–901.CrossRefPubMed
16.
Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22(14):3618–329.CrossRefPubMedPubMedCentral
17.
George J, Walter V, Peifer M, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9(1):1048.CrossRefPubMedPubMedCentral
18.
Tenjin Y, Uramoto H, Kobayasi H, et al. Combined large cell neuroendocrine carcinoma with both adenocarcinoma and squamous cell carcinoma. JJLC. 2015;55:89–92.CrossRef
19.
Derks JL, Leblay N, Thunnissen E, et al. Molecular Subtypes of Pulmonary large-cell neuroendocrine carcinoma predict Chemotherapy Treatment Outcome. Clin Cancer Res. 2018;24(1):33–42.CrossRefPubMed
20.
Oda R, Okuda K, Yamashita Y, et al. Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab. Thorac Cancer. 2020;11(7):2036–9.CrossRefPubMedPubMedCentral
Metadata
Title
Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature
Authors
Zirui Zhu
You Liu
Hengliang Xu
Haoyong Ning
Yanmin Xia
Leilei Shen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2023
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-023-02349-4

Other articles of this Issue 1/2023

Journal of Cardiothoracic Surgery 1/2023 Go to the issue

Research

Managing postoperative atrial fibrillation after open-heart surgery using transdermal β1 blockers

Research

Pulmonary placental transmogrification: a difficult pattern in differential diagnosis of pulmonary hamartomas from a tertiary care hospital in Turkey

Research

Effects of multimodal low-opioid anesthesia protocol during on-pump coronary artery bypass grafting: a prospective cohort study

Research

Assessment of degradability and endothelialization of modified poly L-lactic acid (PLLA) atrial septal defect (ASD) occluders over time in vivo

Case Report

Effectiveness of VA-ECMO plus intra-aortic balloon pump for cardiac shock in patients with type A aortic dissection: a case series

Case Report

Multiple local recurrences of primary sternal chondrosarcoma: tumor manipulation or self-seeding